| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,000 | 6,900 | 21.09. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 9,500 | 175 | |||
| 6,900 | 1.251 | |||
| 6,650 | 80 | |||
| 6,550 | 80 | |||
| 6,450 | 815 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 735 | 6,100 | |||
| 80 | 6,050 | |||
| 1.251 | 6,000 | |||
| 80 | 5,950 | |||
| 80 | 5,850 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 110 | 4,700 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 4.397 | 0,672 | 2.955 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:01:28 | 6,050 | 800 |
| 11:41:55 | 5,600 | 900 |
| Tagesumsatz Xetra | +0,750 +13,76 % | 3.100 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.09. | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | 631 | PR Newswire | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
PR Newswire
LONDON, United Kingdom, September 07
4basebio... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 27.08. | Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors | 23 | Contract Pharma | ||
| 26.08. | 4basebio shares jump on new marketing tie-up with US-based Genezen | 11 | Alliance News | ||
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 370 | GlobeNewswire (Europe) | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through... ► Artikel lesen | |
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 278 | PR Newswire | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mo | Insmed Incorporated: FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 | PR Newswire | -sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study-
-Full Approval Could Bring ARIKAYCE to Patients Earlier in Their... ► Artikel lesen | |
| Mo | EQS-News: Menarini Industrie Farmaceutiche Riunite: Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo (Obicetrapib als Monotherapie) und Evlarco (Fixkombination aus ... | EQS Group (DE) | EQS-News: Menarini Industrie Farmaceutiche Riunite
/ Schlagwort(e): Sonstiges/Sonstiges
Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung... ► Artikel lesen | |
| Mo | Moderna, Inc.: Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026 | ACCESS Newswire | Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential SymposiumModerna to host an investor event... ► Artikel lesen | |
| 01:06 | UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu vaccine (aTIVc) and Extending Health Security Pandemic Agreement | PR Newswire | The new CSL Seqirus-developed vaccine will be introduced to the annual influenza vaccination programme from next year (2027/28).Its introduction marks a significant advance in the evolution of... ► Artikel lesen | |
| Mo | EQS-News: ABIVAX: Abivax Presents Business Updates and First Half 2026 Financial Results | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Half Year Results
Abivax Presents Business Updates and First Half 2026 Financial Results
21.09.2026 / 22:05 CET/CEST
The issuer is solely... ► Artikel lesen |